Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6128543 | 0.93 | OPRK1 (0.43) | OPRK1P2RY12CYP11B2 | |
| SCHEMBL708166 | 0.80 | OPRK1 (0.60) | OPRK1SMN1; SMN2KDM4E | |
| SCHEMBL708167 | 0.80 | OPRK1 (0.60) | OPRK1SMN1; SMN2KDM4E | |
| SCHEMBL10281620 | 0.74 | OPRK1 (0.62) | OPRK1SMN1; SMN2KDM4E | |
| SCHEMBL6125265 | 0.74 | OPRK1 (0.62) | OPRK1SMN1; SMN2KDM4E | |
| SCHEMBL6128551 | 0.74 | OPRK1 (0.37) | OPRK1P2RY12CYP11B2KDM4E | |
| SCHEMBL708078 | 0.73 | OPRK1 (0.64) | OPRK1SMN1; SMN2KDM4E | |
| SCHEMBL708077 | 0.73 | OPRK1 (0.64) | OPRK1SMN1; SMN2KDM4E | |
| SCHEMBL21661132 | 0.72 | OPRK1 (0.44) | OPRK1SMN1; SMN2KDM4E | |
| SCHEMBL10281206 | 0.69 | PSMD14 (0.38) | P2RY12SMN1; SMN2CYP11B2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122835-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-17 | — | — | US | disclosed |
| US-8124606-B2 | Substituted 7,8,9,10-tetrahydro-5H-dipyrido[1,2-a:3′,2′-e]pyrazin-6(6aH)-ones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20110158989-A1 | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122835-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | OPRK1 1194/4885P2RY12 2050/4885SMN1; SMN2 1693/4885 |
| US-20110158989-A1 | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS | PARP1, PARP3, PARP2 | OPRK1 1194/4885P2RY12 2050/4885SMN1; SMN2 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.